Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study

doi:10.21037/atm-21-1340

	Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study
	Shao, Xiying 1,2; Zheng, Yabing 1,2; Cao, Wenming 1,2; Shen, Xiabo 1,2; Li, Guangliang 1,2; Chen, Junqing 1,2; Huang, Yuan 1,2; Huang, Ping 1,2; Shi, Lei 1,2; Ye, Weiwu 1,2
刊名	ANNALS OF TRANSLATIONAL MEDICINE
	2021-04-01
卷号	9
关键词	Ki67 progesterone receptor palbociclib
ISSN号	2305-5839
DOI	10.21037/atm-21-1340
通讯作者	Chen, Zhanhong(czred@sina.com) ; Wang, Xiaojia(wxiaojia0803@163.com)
英文摘要	Background: Palbociclib combined with endocrine therapy has been approved as a front-line treatment for hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC). A key challenge remains to uncover biomarkers to identify those patients who may benefit from palbociclib treatment. Methods: We retrospectively analyzed the values of Ki67 and progesterone receptor (PR) as detected by immunohistochemistry in 81 ABC patients with palbociclib and hormone therapy treatment, and evaluated the impact on progression-free survival (PFS). Results: In the total population, women with Ki67 >= 14% had marginally significantly shorter PFS than those with Ki67 <14% (P=0.062). Patients with Ki67 >= 30% had significantly shorter PFS than those with Ki67 <30% (P=0.048). Meanwhile, PR >= 20% was associated with longer PFS. Moreover, the change of Ki67 or PR from primary tissue to metastatic lesions was related to PFS. As for the hormone therapy subgroup, there were significant associations between Ki67 and PR levels and PFS in the aromatase inhibitors (AIs) subgroup. Patients with Ki67 >= 14% or Ki67 >= 30% had shorter PFS than those with Ki67 < 14% or Ki67 < 30%, respectively (P=0.024, P<0.001). Additionally, the change of Ki67 or PR from primary tissue to metastatic lesions was related to PFS. When both Ki67 and PR were considered, there were significant differences between the different cohorts. Compared with patients with Ki67 >= 14% and PR <20%, those with Ki67 <14% and PR >= 20% had significantly longer PFS. In addition, patients with Ki67 <30% and PR >= 20% had significantly longer PFS than those with Ki67 >= 30% and PR <20%. Furthermore, in the AI cohort, patients with Ki67 <14% and PR >= 20% had significantly longer PFS than those with Ki67 >= 14% and PR <20%. Women with Ki67 <30% and PR >= 20% had significantly longer PFS than those with Ki67 >= 30% and PR <20%. Conclusions: The present study indicates that both Ki67 and PR have great impacts on palbociclib and hormone therapy and may contribute to selecting more effective partners for palbociclib.
资助项目	Zhejiang Provincial Natural Science Foundation[Y2101312] ; Zhejiang Provincial Natural Science Foundation[LY17H160041] ; Zhejiang Provincial Medical Science and Technology Program[2010QNA006] ; Zhejiang Provincial Medical Science and Technology Program[2021KY551] ; Zhejiang science and Technology Program[2016C33199] ; Special Fund of Wu Jieping Medical Foundation Clinical Research[320.670010007]
WOS关键词	ADVANCED BREAST-CANCER ; KINASE 4/6 INHIBITOR ; ESTROGEN-RECEPTOR ; ENDOCRINE THERAPY ; POTENTIAL BIOMARKERS ; CDK4/6 INHIBITORS ; FULVESTRANT ; COMBINATION ; RESISTANCE ; ABEMACICLIB
WOS研究方向	Oncology ; Research & Experimental Medicine
语种	英语
出版者	AME PUBL CO
WOS记录号	WOS:000647719800002
资助机构	Zhejiang Provincial Natural Science Foundation ; Zhejiang Provincial Medical Science and Technology Program ; Zhejiang science and Technology Program ; Special Fund of Wu Jieping Medical Foundation Clinical Research
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/122351]
专题	中国科学院合肥物质科学研究院
通讯作者	Chen, Zhanhong; Wang, Xiaojia
作者单位	1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol Breast Canc, Hangzhou, Peoples R China 2.Chinese Acad Sci, Inst Canc & Basic Med ICBM, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Shao, Xiying,Zheng, Yabing,Cao, Wenming,et al. Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study[J]. ANNALS OF TRANSLATIONAL MEDICINE,2021,9.
APA	Shao, Xiying.,Zheng, Yabing.,Cao, Wenming.,Shen, Xiabo.,Li, Guangliang.,...&Wang, Xiaojia.(2021).Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study.ANNALS OF TRANSLATIONAL MEDICINE,9.
MLA	Shao, Xiying,et al."Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study".ANNALS OF TRANSLATIONAL MEDICINE 9(2021).